ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1659

Systematic Review Of Amyloid Beta-Related Angiitis: A Treatable Cause Of Vasculitis Affecting Central Nervous System

Abhijeet Danve1 and Atul A. Deodhar2, 1Rheumatology, Oregon Health and Science University, Portland, OR, 2Oregon Health and Science University, Portland, OR

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Amyloidosis, cerebrovascular disease and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Vasculitis II

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Amyloid β-related angiitis (ABRA) is a rare type of Central Nervous System Vasculitis (CNSV), which complicates Cerebral Amyloid Angiopathy (CAA).  Data about clinical features, management and outcomes of ABRA are scant. It is important to differentiate this treatable disease from primary CNSV and other irreversible neurological disorders.

Methods:

We searched the OVID Medline database for relevant articles between 1946 to 2012 using the  key words “Cerebral amyloid angiopathy”, “vasculitis” “inflammatory CAA” “Amyloid Beta-Related Angiitis”.    Data from major case series and reviews as well as individual case reports was extracted.  We found total 98 patients who were reported in the literature. Two case reports were in other languages and data was unavailable for 2 other patients.  Demographics, clinical features, lab and imaging findings, treatment and follow up was extracted for 94 patients  and is  summarized descriptively.

Results:

Patients with mean age of 67 years presented acutely (54%) or subacutely (46%) with cognitive or behavioral changes of variable severity (71%), focal deficits (51%), seizures (36%) and headache (35%). More than 2 features were present in 77%. Prior malignancy was reported in 10 patients and associated autoimmune disease (e.g. autoimmune thyroiditis, autoimmune hepatitis, RA and pernicious anemia) in 11. ESR and CRP were elevated in 14 /47 (29.7%); 70% patients (12/17) had ApoE genotype e4/e4   CSF showed elevated protein in 71% (42/59) and lymphocytic pleocytosis in 44% (26/ 59) and abnormalities normalized after treatment in 2/2 patients.  Brain MRI was abnormal in 97.4 % (75/77) and typically showed asymmetrical bilateral white matter hyperintensity on T2W and FLAIR (88%), cortical microbleeds in 87% (21/24) on SWI and minimally enhancing mass like lesions (26%).  Post treatment MRI showed improvement in 38/47 (80%) patients. Brain biopsy confirmed diagnosis in 97.8% (92/94) patients which showed transmural inflammation with deposition of A Β-amyloid in vessels in 80% and pervasculitis in 20% patients. Of 73 patients who received corticosteroids 78% showed either partial or complete clinical improvement. Cyclophosphamide (34%), azathioprine (6.6%), methotrexate (2%) and mycophenolate (2%) were also used successfully in conjunction with steroids. Relapse occurred in 26% of 57 patients, either after reduction or cessation of therapy and responded well after retreatment. 

Conclusion:

ABRA is a rare, but treatable cause of progressive dementia and neurological dysfunction in elderly and should be considered in the differential diagnosis of rapid onset neurological disease . It has characteristic MRI findings and responds well to steroids and immunosuppressants. 

Study

Scolding et al

Kinnecom

et al

Salvarani et al

Chung et al

Others

Total

No of patients

34

14

8

16

22

94

Age

67.3 (43-82)*

63.2 (45-79)*

63 (42-84) *

69 (46-83)**

67.6 (52-87)*

65.2 (42-87)*

Sex (M/F)

17/17

9/5

6/2

7/9

11/11

50/44

Clinical features

CB change

Seizures

Focal deficits

Headache

 

29/34

8/34

15/34

12/34

9/12

7/12

1/12

6/12

6/8

0/8

7/8

4/8

9/16

7/16

9/16

7/16

 

13/22

12/22

15/22

4/22

66/92 (71%)

34/92 (36%)

47/92 (51%)

33/92 (35%)

ApoE e4/e4

NA

10/13

NA

NA

2/4

12/17 (70%)

CSF

Elevated proteins

Pleocytosis

Oligoclonal bands

Repeat CSF

11/18

8/18

12/21

4/5

1/5

NA

7/8

5/8

NA

8/11

5/11

1/1

12/17

7/17

3/3

 

42/59 (71%)

26/59 (44%)

16/16(100%)

 

MRI

White matter changes#

Microbleed on SWI/GEI

Enhancement

Improvement with Rx

 

13/20

4

7/10

4/5

12/12

6/7

NA

10/12

6/8

NA

5/8

4/6

14/14

4/4

5/9

6/9

21/21

11/13

6/11

13/15

66/75(88%)

21/24(87%)

23/38 (60%)

37/47 (79%)

Pathology

Vasculitis or perivasculitis

34/34

14/14

8/8

16/16

19/20‡‡

91/92 (99%)

Response to therapy

12/20

10/12

6/8

10/12

19/20

57/72 (79%)

Relapse

NA

3/12

2/8

NA

3/14∞

8/34 (23%)

*Mean (range) age     **Median (range) age

# Hyperintesnsities on T2W or FLAIR 

SWI Susceptibility weighted imaging

CB- Cognitive behavioral  

‡‡ 2 patients were treated presumptively

∞ As per the information wherever it was reported


Disclosure:

A. Danve,
None;

A. A. Deodhar,

AbbVie, Merck-Sharp-Dohme, Pfizer and UCB,

5,

AbbVie, Merck-Sharp-Dohme, Pfizer and UCB,

8,

AbbVie, Amgen, Novartis, UCB,

2.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/systematic-review-of-amyloid-beta-related-angiitis-a-treatable-cause-of-vasculitis-affecting-central-nervous-system/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology